View Rule

View EO 12866 Meetings Printer-Friendly Version     Download RIN Data in XML

SSA RIN: 0960-AF88 Publication ID: Fall 2014 
Title: Revised Medical Criteria for Evaluating Hematological Disorders (974F) 
Abstract:

Sections 7.00 and 107.00, Hematological Disorders, of appendix 1 to subpart P of part 404 of our regulations, describe hematological disorders that we consider severe enough to prevent a person from performing any gainful activity or that cause marked and severe functional limitation for a child claiming Supplemental Security Income payments under title XVI. We are proposing to revise the criteria in these sections to ensure that the medical evaluation criteria are up-to-date and consistent with the latest advances in medical knowledge and treatment.

 
Agency: Social Security Administration(SSA)  Priority: Other Significant 
RIN Status: Previously published in the Unified Agenda Agenda Stage of Rulemaking: Final Rule Stage 
Major: No  Unfunded Mandates: No 
CFR Citation: 20 CFR 404.1500, app 1   
Legal Authority: 42 USC 402    42 USC 405(a)    42 USC 405(b)    42 USC 405(d) to 405(h)    42 USC 416(i)    42 USC 421(a)    42 USC 421(i)    42 USC 423    42 USC 902(a)5)    42 USC 1381a    42 USC 1382c    42 USC 1383    42 USC 1383b   
Legal Deadline:  None

Statement of Need: These final rules are necessary to update the hematological listings to reflect advances in medical knowledge, treatment, and methods of evaluating hematological disorders. The changes ensure that determinations of disability have a sound medical basis, that claimants receive equal treatment through the use of specific criteria, and that people who are disabled can be readily identified and awarded benefits if all other factors of entitlement or eligibility are met.

Summary of the Legal Basis: Administrative--not required by statute or court order.

Alternatives: We considered not revising the listings or making only minor technical changes and continuing to use our current criteria. However, we believe that these revisions are preferable because of the medical advances that have been made in treating and evaluating these types of impairments.

Anticipated Costs and Benefits: Estimated savings--low.

Risks: None.

Timetable:
Action Date FR Cite
NPRM  11/19/2013  78 FR 69324   
NPRM Comment Period End  01/21/2014 
Final Action  09/00/2015 
Additional Information: Includes Retrospective Review under E.O. 13563.
Regulatory Flexibility Analysis Required: No  Government Levels Affected: None 
Small Entities Affected: No  Federalism: No 
Included in the Regulatory Plan: Yes 
Public Comment URL: www.regulations.gov  
RIN Data Printed in the FR: No 
Agency Contact:
Cheryl A. Williams
Director
Social Security Administration
Office of Medical Policy, 6401 Security Boulevard,
Baltimore, MD 21235-6401
Phone:410 965-1020
Email: cheryl.a.williams@ssa.gov

Mark Kuhn
Social Insurance Specialist
Social Security Administration
Office of Medical Listings Improvement, 6401 Security Boulevard,
Baltimore, MD 21235-6401
Phone:410 966-6109

Brian Rudick
Social Insurance Specialist, Regulations Writer
Social Security Administration
Office of Regulations and Reports Clearance, 6401 Security Boulevard,
Baltimore, MD 21235-6401
Phone:410 965-1483
Email: brian.rudick@ssa.gov